Confirmed tumor response (complete response [CR] or partial response [PR]) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by IRAC

Participants who received ADP-A2M4CD8. No subject images were assessed by Independent Reviewer due to lack of efficacy observed on Investigator review. Thus, no results are reported.

An AE was defined as any untoward medical occurrence in a subject or clinical study participant temporally associated with the use of the study intervention, whether or not considered related to the study intervention. Therefore, an AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants with AEs (including SAEs), SAEs and AESI including cytokine release syndrome, ICANS, and prolonged cytopenia are presented.

Participants who received ADP-A2M4CD8

TTR (CR or PR) was defined as the interval between the date of first T-cell infusion and the earliest date of first documented confirmed CR or confirmed PR.

Participants who received ADP-A2M4CD8 and had a confirmed CR or PR. No subjects had a confirmed CR or PR. Thus, no results are reported.

DoR is defined as duration between the initial date of the confirmed complete or partial response to the date of progressive disease or death, where tumor response and disease progression were assessed by IRAC.

Participants who received ADP-A2M4CD8 and had a confirmed CR or PR. No subjects had a confirmed CR or PR. Thus, no results are reported.

BOR is the best response recorded from the start of T-cell infusion until disease progression as assessed by IRAC. Response categories are confirmed CR, confirmed PR, stable disease (SD) and confirmed progressive disease (PD).

Participants who received ADP-A2M4CD8. No subject images were assessed by Independent Reviewer due to lack of efficacy observed on Investigator review. Thus, no results are reported.

PFS is defined as time from the T-cell infusion to the date of the first documentation of progressive disease (PD) as assessed by IRAC or death due to any cause, whichever occurs first.

Participants who received ADP-A2M4CD8. No subject images were assessed by IRAC due to lack of efficacy observed on Investigator review. Hence, no results are reported.

Confirmed tumor response (complete response [CR] or partial response [PR]) to treatment as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment

Participants who received ADP-A2M4CD8.

TTR (CR or PR) was defined as the interval between the date of first T-cell infusion and the earliest date of first documented confirmed CR or confirmed PR

Participants who received ADP-A2M4CD8 and had a confirmed CR or PR. No subjects had a confirmed CR or PR. Thus, TTR was not calculated, and no results are reported.

DoR is defined as duration between the initial date of the confirmed complete or partial response to the date of progressive disease or death, where tumor response and disease progression were assessed by Investigator Assessment.

Participants who received ADP-A2M4CD8 and had a confirmed CR or PR. No subjects had a confirmed CR or PR. Thus, DoR was not calculated, and no results are reported.

BOR is the best response recorded from the start of T-cell infusion until disease progression as assessed by the Investigator. Response categories are confirmed CR, confirmed PR, stable disease (SD) and confirmed progressive disease (PD).

Participants who received ADP-A2M4CD8.

PFS is defined as the time from the T-cell infusion to the date of the first documentation of progressive disease (PD) as assessed by investigator assessment or death due to any cause, whichever occurs first.

Participants who received ADP-A2M4CD8

OS is defined as the time from the date of first T-cell infusion to the date of death (due to any cause).

Participants who received ADP-A2M4CD8

The presence of RCL was assessed by qPCR targeting a segment of the vesicular stomatitis virus glycoprotein (VSV G) coding sequence. 1 participant had at least 1 post-infusion sample tested for RCL.

The count of participants with RCL post-infusion is presented.

Participants who received ADP-A2M4CD8 and had a post-infusion sample tested for VSV-G

Deoxyribonucleic acid (DNA) from participants peripheral blood mononuclear cell (PBMC) samples are subjected to lentiviral vector integration site analysis by next-generation sequencing, thus evaluating both the clonality status of the transduced cell population and the genomic localization of individual integration sites. The outcome measure is the number of participants with integration sites representing more than 5% of all unique sites.

Participants who received ADP-A2M4CD8 and had a sample analyzed for IO. All subjects died prior to 1 year post T-cell infusion, subsequently no samples were obtained or analyzed.

Peak persistence of ADP-A2M4CD8 cells was reported as vector copy numbers per microgram of genomic DNA from peripheral blood mononuclear cell (PBMC).

Participants who received ADP-A2M4CD8

Time from ADP-A2M4CD8 T-cell infusion to peak persistence of cells.

Participants who received ADP-A2M4CD8

Concordance of the MAGE A-4 clinical trial assay and in vitro diagnostic (IVD) kit.

Due to study termination, an IVD kit for companion diagnosis was not developed. Thus, there is no data to report regarding concordance of the MAGE A-4 clinical trial assay and the IVD companion diagnostic kit.